To deliver the first medical treatment dedicated to patients with haemorrhagic s...
To deliver the first medical treatment dedicated to patients with haemorrhagic stroke
The NANOp2lysis platform is a deep-tech technology to protect active enzymes by a reversible precipitation and to produce solid-state nanoparticles. Such particles can then be loaded at high concentration into tailored carrier (wi...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RESOLVE
tPA Nanoconstructs for Treating Acute Ischemic Stroke a Tec...
150K€
Cerrado
PCI2022-134986-2
THERAGNOSTIC TARGETING OF EXTRACELLULAR MATRIX METALLOPROTEI...
175K€
Cerrado
IMPACT
IMproved Plasminogen Activator based on Cerium oxide nanopar...
212K€
Cerrado
SAF2014-56336-R
NANONEUROPROTECCION TERMO-MOLECULAR VECTORIZADA EN LA ISQUEM...
218K€
Cerrado
BIONICS
A biomimetic and neuroprotective delivery nanocapsule for th...
168K€
Cerrado
SAF2008-02190
NANOTECNOLOGIA APLICADA EN EL ICTUS: NANOPARTICULAS LIPIDICA...
85K€
Cerrado
Información proyecto OP2DRAIN
Duración del proyecto: 20 meses
Fecha Inicio: 2022-10-26
Fecha Fin: 2024-06-30
Líder del proyecto
Op2Lysis
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
11M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The NANOp2lysis platform is a deep-tech technology to protect active enzymes by a reversible precipitation and to produce solid-state nanoparticles. Such particles can then be loaded at high concentration into tailored carrier (with specific targeting / slow delivery characteristics).
O2L-001 (derived from NANOp2Lysis) is the first effective and safe treatment to remove intracerebral hematoma and reduce disability and death following acute hemorrhagic stroke (AHS). It has been tailored to be locally injected, after micro-invasive surgery, via a catheter at the core of the hematoma. The in vivo gelation of the product at body temperature allows a local and slow delivery of our new thrombolytic agent, OptPA. The main characteristics of O2L-001 are thus the following:
- EASY. simplified model of administration (unique injection)
- EFFICIENT. better thrombolytic effect on best translational model (vs gold standard)
- SAFE. reduced side effect (bleeding and neurotoxoxicity vs gold standard)